KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Vertex Pharmaceuticals (VRTX) over the last 9 years, with Q4 2017 value amounting to $5.2 million.

  • Vertex Pharmaceuticals' Current Deferred Revenue fell 1392.17% to $5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was $5.2 million, marking a year-over-year decrease of 1392.17%. This contributed to the annual value of $5.2 million for FY2017, which is 1392.17% down from last year.
  • As of Q4 2017, Vertex Pharmaceuticals' Current Deferred Revenue stood at $5.2 million, which was down 1392.17% from $13.0 million recorded in Q3 2017.
  • Vertex Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $35.5 million during Q1 2013, with a 5-year trough of $5.2 million in Q4 2017.
  • Over the past 5 years, Vertex Pharmaceuticals' median Current Deferred Revenue value was $15.4 million (recorded in 2015), while the average stood at $17.5 million.
  • In the last 5 years, Vertex Pharmaceuticals' Current Deferred Revenue plummeted by 6315.05% in 2016 and then soared by 4061.86% in 2017.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Current Deferred Revenue stood at $21.5 million in 2013, then dropped by 18.79% to $17.5 million in 2014, then dropped by 6.71% to $16.3 million in 2015, then plummeted by 63.15% to $6.0 million in 2016, then decreased by 13.92% to $5.2 million in 2017.
  • Its last three reported values are $5.2 million in Q4 2017, $13.0 million for Q3 2017, and $7.3 million during Q2 2017.